ANESTACON

Post-LOE

lidocaine hydrochloride

Pfizer

ANDATOPICALJELLY

Approved

Apr 1974

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ANESTACON (lidocaine hydrochloride) by Pfizer is mechanism of action lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1974.

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

Indications (7)

regional anesthesia analgesia for surgery dental

Worked on ANESTACON at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ANESTACON

Mechanism of Action

Indications (7)

Clinical Trials (1)